Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leukocyte adhesion molecules (CAMs) on the endothelium are a family of cell surface proteins that mediate the adhesion of leukocytes to the endothelium, a critical step in the inflammatory response. These molecules, including selectins, immunoglobulin superfamily members (ICAMs, VCAMs), and integrins, orchestrate the sequential steps of leukocyte recruitment, enabling immune cells to migrate from the bloodstream into tissues. Dysregulation of CAM expression contributes to chronic inflammatory disorders and vascular diseases, making them potential therapeutic targets, although challenges remain in developing effective and safe CAM-targeting drugs.
Blocking CAM-ligand interactions to inhibit leukocyte adhesion and migration.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leukocyte Adhesion Molecules on Endothelium (CAMs).